Haemonetics Corporation, a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has completed the previously announced sale of its whole blood assets to GVS, S.p.A (“GVS”), one of the world’s leading manufacturers of filter solutions for applications in the healthcare and life sciences sectors.
In connection with the closing of this transaction, GVS has acquired Haemonetics’ portfolio of proprietary whole blood collection, processing and filtration solutions, along with Haemonetics’ manufacturing facility in Covina, California where certain of these products are produced, and related equipment and assets located at Haemonetics’ manufacturing facility in Tijuana, Mexico.
The transaction comprises a total cash consideration of up to $67.8M, including $45.3M upfront after giving effect to certain customary adjustments, and up to $22.5M in contingent earn-outs over the next four years. The Company intends to use the proceeds from this transaction for general corporate purposes and additional investments in growth initiatives. Haemonetics will provide further details regarding the financial impact of this transaction on its fiscal year 2025 guidance during its third-quarter earnings call, scheduled for February 6, 2025, at 8:00 AM ET.
Haemonetics’ Blood Center business will continue to manufacture and provide customers with its full line of apheresis solutions for automated blood collection. These include devices and disposable kits that support a variety of apheresis collections, including platelets, plasma and red cells, and ensure efficient blood center operations.